PT - JOURNAL ARTICLE AU - Murphy, T AU - Waterhouse, D AU - James, S AU - Casey, C AU - Fitzgerald, E AU - O’Connell, E AU - Watson, C AU - Gallagher, J AU - Ledwidge, M AU - McDonald, K TI - 60 A comparison of HFrEF vs HFpEF’s clinical workload and cost in the first year following hospitalisation and enrollment in a disease management program AID - 10.1136/heartjnl-2016-310523.60 DP - 2016 Oct 01 TA - Heart PG - A31--A32 VI - 102 IP - Suppl 9 4099 - http://heart.bmj.com/content/102/Suppl_9/A31.2.short 4100 - http://heart.bmj.com/content/102/Suppl_9/A31.2.full SO - Heart2016 Oct 01; 102 AB - Background Admission with heart failure (HF) is a milestone in the progression of the disease, often resulting in higher intensity medical care and ensuing readmissions. Whilst there is evidence supporting enrolling patients in a heart failure disease management program (HF-DMP), not all reported HF-DMPs have systematically enrolled patients with HF with preserved ejection fraction (HFpEF) and there is a scarcity of literature differentiating costs based on HF-phenotype.Methods 1292 consenting, consecutive patients admitted with a primary diagnosis of HF were enrolled in a hospital based HF-DMP and categorised as HFpEF (EF ≥ 45%) or HFrEF (EF < 45%). Hospitalizations, primary care, medications, and DMP workload with associated costs were evaluated assessing DMP clinic visits, telephonic contact, medication changes over 1 year using a mixture of casemix and micro-costing techniques.Results The total average annual cost per patient was marginally higher in patients with HFrEF €13,011 (12011, 14078) than HFpEF, €12206 (11009, 13518). However, emergency non-cardiovascular admission rates and average cost per patient were higher in the HFpEF vs HFrEF group (0.46 vs 0.31 per patient/12 months). In the first 3 months of the outpatient HF-DMP the HFrEF population cost more on average €791(764,819) vs €693(660,728).Conclusion There are greater short-term (3 month) costs of HFrEF versus HFpEF as part of a HF-DMP following an admission. However, long-term (3–9 month) costs of HFpEF are greater because of higher non-cardiovascular rehospitalisations. As HFpEF becomes the dominant form of HF, more work is required in HF-DMPs to address non-cardiovascular rehospitalisations and to integrate hospital based HF-DMPs into primary healthcare structures.